NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Allergan Pharmaceuticals Ireland (dexamethasone)	 Board of Community Health Councils in Wales British National Formulary
Patient/carer groups	Care Quality Commission
Action for Blind People	Commissioning Support Appraisals
Afiya Trust	Service
Association of Blind Asians (ABA)	Department of Health, Social Services
Black Health AgencyChinese National Healthy Living Centre	 and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency
Counsel and Care	 National Association of Primary Care
Equalities National Council	 Public Health Wales NHS Trust
Eyecare Trust	NHS Alliance
Fight for Sight	 NHS Commercial Medicines Unit
Macular Disease Society	 NHS Confederation
Muslim Council of Britain	 NHS Quality Improvement Scotland
Muslim Health Network	 Scottish Medicines Consortium
 Organisation of Blind African 	
Caribbeans	Possible comparator manufacturers
 Royal National Institute of Blind 	 Bristol Myers Squibb (triamcinolone)
People (RNIB)	 Carl Zeiss Ltd (photocoagulation)
Seeability	 Coherent UK (photocoagulation)
• Sense	 KLS Martin Group (photocoagulation)
South Asian Health Foundation	 Litechnica (photocoagulation)
Specialised Healthcare Alliance	 Lumenis (UK) (photocoagulation)
Specific Eye Conditions (SPECS)	 Quantel Medical (photocoagulation)
 Thomas Pocklington Trust 	 Roche Products (bevacizumab)
	Topcon Great Britain (photocoagulation)
<u>Professional groups</u>	
British Association for Services to the	Relevant research groups
Elderly	 Institute of Ophthalmology, University
British Geriatrics Society	College London
College of Optometrists	 MRC Clinical Trials Unit

National Institute for Health and Clinical Excellence

Matrix for the technology appraisal of dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Issue date: July 2010 Page 1 of 3

Consultees Commentators (no right to submit or appeal) Royal College of General Practitioners National Institute for Health Research Royal College of Nursing Policy Research Institute on Ageing and Royal College of Ophthalmologists Ethnicity Royal College of Pathologists Research Institute for the Care of Older People Royal College of Physicians Royal Pharmaceutical Society **Evidence Review Group** Royal Society of Medicine -Aberdeen HTA Group Intellectual Disabilities Forum National Institute for Health Research United Kingdom Clinical Pharmacy Health Technology Assessment Association Programme Others Associated Guideline Groups Department of Health National Clinical Guidelines Centre Aneurin Bevan Health Board NHS Waltham Forest Associated Public Health Groups Welsh Assembly Government None

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence Matrix for the technology appraisal of dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Issue date: July 2010 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence Matrix for the technology appraisal of dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion

Issue date: July 2010 Page 3 of 3

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.